Published in Am J Kidney Dis on April 26, 2013
C4d as a Diagnostic Tool in Proliferative GN. J Am Soc Nephrol (2015) 1.03
Dense deposit disease and C3 glomerulopathy. Semin Nephrol (2013) 0.98
Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol (2015) 0.96
Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol (2013) 0.95
Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int (2015) 0.84
Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias. Clin J Am Soc Nephrol (2016) 0.81
Update on membranoproliferative GN. Clin J Am Soc Nephrol (2014) 0.78
Recovery of renal function succeeding stem cell transplant: a case of C3 Glomerulonephiritis secondary to monoclonal gammopathy. Clin Kidney J (2013) 0.78
Outcome of patients with primary immune-complex type mesangiocapillary glomerulonephritis (MCGN) in Cape Town South Africa. PLoS One (2014) 0.77
C3 Glomerulopathy. Pediatr Nephrol (2016) 0.76
Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol (2016) 0.76
Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol (2016) 0.76
Crescentic acute glomerulonephritis with isolated C3 deposition: a case report and review of literature. Int J Clin Exp Pathol (2015) 0.75
C3 glomerulopathy. F1000Res (2017) 0.75
Membranoproliferative glomerulonephritis: the times they are a-changin'. Clin Exp Nephrol (2013) 0.75
A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine. Clin J Am Soc Nephrol (2016) 0.75
C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome. Clin Kidney J (2016) 0.75
C3 glomerulonephritis in multiple myeloma: A case report and literature review. Medicine (Baltimore) (2016) 0.75
Monoclonal gammopathy of renal significance: Diagnostic workup. World J Nephrol (2017) 0.75
C3 glomerulopathy associated to multiple myeloma successfully treated by autologous stem cell transplant. Indian J Nephrol (2017) 0.75
Atypical Plasmacytic Proliferation in a Case of C3 Glomerulopathy: Pathophysiology Demystified. J Investig Med High Impact Case Rep (2017) 0.75
Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity. Int Urol Nephrol (2017) 0.75
C3 glomerulopathy and current dilemmas. Clin Exp Nephrol (2016) 0.75
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Complement regulators and inhibitory proteins. Nat Rev Immunol (2009) 4.46
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet (2006) 3.24
C3 glomerulopathy: a new classification. Nat Rev Nephrol (2010) 3.17
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet (2005) 2.92
Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med (2012) 2.67
Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int (2011) 2.61
Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol (2001) 2.54
Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol (2009) 2.45
Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol (2008) 2.08
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int (2012) 1.81
Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol (2012) 1.70
Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol (2011) 1.58
Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis (2010) 1.57
Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med (1992) 1.56
Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol (1999) 1.51
Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol (2010) 1.42
Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol (2011) 1.38
Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol (2011) 1.31
Dense deposit disease in association with monoclonal gammopathy of unknown significance. Nephrol Dial Transplant (1996) 0.97
A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome. Nephrol Dial Transplant (2010) 0.95
Membranoproliferative glomerulonephritis in association with chronic lymphocytic leukaemia: a report of three cases. Pathology (2002) 0.93
Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia. Leuk Res (2011) 0.86
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A (2005) 13.44
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med (2013) 5.67
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum (2012) 4.80
Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 3.85
Forty-six genes causing nonsyndromic hearing impairment: which ones should be analyzed in DNA diagnostics? Mutat Res (2008) 3.76
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol (2012) 2.83
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol (2011) 2.72
Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med (2012) 2.67
GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet (2005) 2.63
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene (2004) 2.62
Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int (2011) 2.61
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol (2004) 2.53
Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat (2010) 2.44
Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med (2011) 2.42
SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes. Proc Natl Acad Sci U S A (2004) 2.41
Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int (2012) 2.28
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation (2013) 2.10
Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol (2010) 2.09
The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med (2010) 2.06
Pirfenidone for diabetic nephropathy. J Am Soc Nephrol (2011) 2.04
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum (2012) 1.99
An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol (2014) 1.95
Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation (2008) 1.92
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol (2011) 1.92
A forward genetics screen in mice identifies recessive deafness traits and reveals that pejvakin is essential for outer hair cell function. J Neurosci (2007) 1.90
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 1.89
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol (2012) 1.87
Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int (2012) 1.81
Prestin, a cochlear motor protein, is defective in non-syndromic hearing loss. Hum Mol Genet (2003) 1.80
Prevalence and evolutionary origins of the del(GJB6-D13S1830) mutation in the DFNB1 locus in hearing-impaired subjects: a multicenter study. Am J Hum Genet (2003) 1.79
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int (2013) 1.79
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma (2010) 1.78
Branchio-oto-renal syndrome: the mutation spectrum in EYA1 and its phenotypic consequences. Hum Mutat (2004) 1.77
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood (2012) 1.75
Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol (2006) 1.75
Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest (2012) 1.74
Chronic renal dysfunction late after liver transplantation. Liver Transpl (2002) 1.74
Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol (2012) 1.70
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology. Am J Surg Pathol (2009) 1.68
Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum Mutat (2003) 1.67
Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest (2008) 1.67
Advancing genetic testing for deafness with genomic technology. J Med Genet (2013) 1.66
Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice. Am J Hum Genet (2008) 1.65
Differential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo. Anesthesiology (2004) 1.65
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int (2011) 1.62
Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med (2006) 1.61
Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2010) 1.60
Transcriptional control of SLC26A4 is involved in Pendred syndrome and nonsyndromic enlargement of vestibular aqueduct (DFNB4). Am J Hum Genet (2007) 1.59
Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol (2011) 1.58
Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis (2010) 1.57
Postinfectious glomerulonephritis in the elderly. J Am Soc Nephrol (2010) 1.57
Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. Crit Care (2014) 1.57